New heart failure guidance stresses four pillars of management
ARNI now perferred over ACEi, and SGLT2i makes an entrance
New Australian guidance on heart failure management recommends a four-drug-class approach in patients with heart failure with reduced ejection fraction (HFrEF).
The consensus statement on the current pharmacological prevention and management of heart failure prioritises the following four drug classes in combination in all patients with heart failure with reduced left ventricular ejection fraction (LVEF ≤ 40%) (HFrEF).